Delivery Order SPE2DB24D3015-SPE2DB25FGAHF
- Not listed
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 tablets per unit. This competitively awarded, non-set-aside contract carries a firm fixed price ceiling value of $2,662.07 and is scheduled for completion by July 23, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,401.41 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantity 30s. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, completed on July 28, 2025. The contract was issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle that runs...
- The Defense Logistics Agency awarded a delivery order valued at $27,184.05 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. XELJANZ XR is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,491.03 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets (30-count units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 22, 2025. The contract represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government, with performance taking place at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAHFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. XELJANZ XR is a rheumatoid arthritis treatment, reflecting the company's extensive portfolio of specialty medications supporting federal healthcare requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 7/28/25 |